For CSF Tau/Aβ42 ratio, which is a powerful predictor for AD and progression, we found a marginally significant improvement when the genetic information was included (adjusted: r = 0.357 vs. unadjusted: r = 0.318; p = 0.071, 95 % CI: -0.083, 0.003, Table 2). The gene discussed is MAPT; the disease is Alzheimer disease.